Minoo Battiwalla
Overview
Explore the profile of Minoo Battiwalla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
2559
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roloff G, Aldoss I, Kopmar N, Lin C, Dekker S, Gupta V, et al.
J Clin Oncol
. 2024 Oct;
43(5):558-566.
PMID: 39418622
Purpose: On the basis of the results of the ZUMA-3 trial, brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor T-cell therapy, gained US Food and Drug Administration approval in October...
2.
Battiwalla M, Tees M, Tees M, Flinn I, Flinn I, Pantin J, et al.
Blood Adv
. 2024 Oct;
9(2):429-435.
PMID: 39418599
We analyzed access barriers to anti-CD19+ chimeric antigen receptor T cells (CARTs) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. A total of 357 intended...
3.
Battiwalla M, Chao J, Cox T, Cruz J, Donnellan W, Eghtedar A, et al.
Clin Hematol Int
. 2024 Oct;
6(4):43-52.
PMID: 39417014
The treatment setting influences acute myeloid leukemia (AML) outcomes. Most cancer patients receive care in the community, yet few studies have evaluated the effectiveness of clinical programs outside of academic...
4.
Aldoss I, Roloff G, Faramand R, Kopmar N, Lin C, Advani A, et al.
Blood Adv
. 2024 Aug;
8(23):6139-6147.
PMID: 39093952
The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189...
5.
Ustun C, Chen M, Kim S, Auletta J, Batista M, Battiwalla M, et al.
Bone Marrow Transplant
. 2023 Oct;
59(1):76-84.
PMID: 37903992
Post-transplant cyclophosphamide (PTCy) is increasingly used to reduce graft-versus-host disease after hematopoietic cell transplantation (HCT); however, it might be associated with more infections. All patients who were ≥2 years old,...
6.
Murthy H, Zhang M, Chen K, Ahmed S, Deotare U, Ganguly S, et al.
Blood Adv
. 2023 Oct;
7(22):7007-7016.
PMID: 37792849
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with a poor prognosis and considered incurable with conventional chemotherapy. Small observational studies reported allogeneic hematopoietic cell transplantation (allo-HCT)...
7.
Egloff S, Cao X, Lachs R, Martin C, Mattlin M, Fennell E, et al.
Leuk Lymphoma
. 2023 Sep;
64(13):2101-2112.
PMID: 37680012
Management of higher-risk myelodysplastic syndromes (HR-MDS) is challenging in the real world. We studied 200 patients with HR-MDS within a large US community hospital network. We describe the clinical presentation,...
8.
Tamari R, McLornan D, Ahn K, Estrada-Merly N, Hernandez-Boluda J, Giralt S, et al.
Blood Adv
. 2023 May;
7(15):3993-4002.
PMID: 37134306
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in...
9.
Boyiadzis M, Zhang M, Chen K, Abdel-Azim H, Abid M, Aljurf M, et al.
Leukemia
. 2023 Mar;
37(5):1173.
PMID: 36949156
No abstract available.
10.
Ragon B, Shah M, DSouza A, Estrada-Merly N, Gowda L, George G, et al.
Blood Adv
. 2023 Feb;
7(12):2746-2757.
PMID: 36827681
The overall survival (OS) has improved significantly in multiple myeloma (MM) over the last decade with the use of proteasome inhibitor and immunomodulatory drug-based combinations, followed by high-dose melphalan and...